In this free webinar, explore insights into targeted protein degradation (TPD) and learn new avenues for enhanced treatment efficacy through selective protein removal. TPD, a strategy that utilizes the native protein homeostasis (or proteostasis) machinery to deplete proteins of interest (POI), represents a novel and promising therapeutic approach. Among them, ubiquitin-proteasomal degradation (UPD) is the most developed one. Attendees will learn about the current stage of UPD drug discovery and more.
TORONTO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- Discover a webinar delving into targeted protein degradation (TPD), an approach using cellular machinery to selectively remove proteins, promising more effective treatments with minimized side effects. The main classical small molecule drug discovery strategies are inhibiting the biological function of proteins of interest, which either block the active pocket or change the protein conformation. However, the significant disadvantages such as limitations in target candidates, dose issues and quick resistance foundations, are calling for a more preferable therapy with fewer side effects.
TPD, a strategy that utilizes the native protein homeostasis (or proteostasis) machinery to deplete proteins of interest (POI), represents a novel and promising therapeutic approach. Among them, ubiquitin-proteasomal degradation (UPD) is the most developed one. The core of UPD is bifunctional molecules, which can be small molecules, molecule chimeras or macromolecules, and harbor the ability to recognize and bind to both the target protein and the crucial components of ubiquitin ligase, by which the target protein is consequently specifically degraded. One bifunctional molecule can trigger multiple rounds of TPD.
Due to its advantages in low application dose and side effects, and the ability to make the 'undruggable' druggable with less concern about direct activity inhibition, UPD drug development pipelines have increased dramatically in recent years for a variety of indications, including cancer, autoimmunity, neurodegeneration infections as well as agriculture.
To develop UPD drugs, both degrader components as well as target proteins are essential and are the start. Efficient and highly customized protein production will be a strong engine that can boost UPD drug discovery. GenScript has production experience on more than 200 ubiquitin ligase constructs and has provided thousands of high-quality target protein candidates.
Join this webinar to explore insights into TPD and learn new avenues for enhanced treatment efficacy through selective protein removal.
Join Yongheng Huang, Doctor in Biochemistry, Protein Senior Scientist, GenScript, for the live webinar on Thursday, January 11, 2024, at 9am EST (3pm CET/EU-Central).
For more information, or to register for this event, visit Enhancing Treatments using Targeted Protein Degradation.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article